Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
292 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Huntington Disease - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Pipeline Review, H2 2016, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10, 5, 46 and 17 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 19 and 4 molecules, respectively.Huntington Disease. Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 5 Huntington Disease Overview 6 Therapeutics Development 7 Huntington Disease - Therapeutics under Development by Companies 9 Huntington Disease - Therapeutics under Investigation by Universities/Institutes 13 Huntington Disease - Pipeline Products Glance 15 Huntington Disease - Products under Development by Companies 18 Huntington Disease - Products under Investigation by Universities/Institutes 23 Huntington Disease - Companies Involved in Therapeutics Development 24 Huntington Disease - Therapeutics Assessment 80 Drug Profiles 91 Huntington Disease - Dormant Projects 260 Huntington Disease - Discontinued Products 268 Huntington Disease - Product Development Milestones 269 Appendix 279
List of Tables
Number of Products under Development for Huntington Disease, H2 2016 19 Number of Products under Development for Huntington Disease - Comparative Analysis, H2 2016 20 Number of Products under Development by Companies, H2 2016 21 Number of Products under Development by Companies, H2 2016 (Contd..1) 22 Number of Products under Development by Companies, H2 2016 (Contd..2) 23 Number of Products under Development by Companies, H2 2016 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H2 2016 26 Comparative Analysis by Late Stage Development, H2 2016 27 Comparative Analysis by Clinical Stage Development, H2 2016 28 Comparative Analysis by Early Stage Development, H2 2016 29 Products under Development by Companies, H2 2016 30 Products under Development by Companies, H2 2016 (Contd..1) 31 Products under Development by Companies, H2 2016 (Contd..2) 32 Products under Development by Companies, H2 2016 (Contd..3) 33 Products under Development by Companies, H2 2016 (Contd..4) 34 Products under Investigation by Universities/Institutes, H2 2016 35 Huntington Disease - Pipeline by Addex Therapeutics Ltd, H2 2016 36 Huntington Disease - Pipeline by AFFiRiS AG, H2 2016 37 Huntington Disease - Pipeline by Angita BV, H2 2016 38 Huntington Disease - Pipeline by Annexon Inc, H2 2016 39 Huntington Disease - Pipeline by Astellas Pharma Inc, H2 2016 40 Huntington Disease - Pipeline by Azevan Pharmaceuticals Inc, H2 2016 41 Huntington Disease - Pipeline by BioCrea GmbH, H2 2016 42 Huntington Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 43 Huntington Disease - Pipeline by Celon Pharma Sp z oo, H2 2016 44 Huntington Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 45 Huntington Disease - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 46 Huntington Disease - Pipeline by EncephRx Inc, H2 2016 47 Huntington Disease - Pipeline by Evotec AG, H2 2016 48 Huntington Disease - Pipeline by Galenea Corp, H2 2016 49 Huntington Disease - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 50 Huntington Disease - Pipeline by Horizon Pharma Plc, H2 2016 51 Huntington Disease - Pipeline by Immungenetics AG, H2 2016 52 Huntington Disease - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 53 Huntington Disease - Pipeline by Ipsen SA, H2 2016 54 Huntington Disease - Pipeline by Kadmon Corp LLC, H2 2016 55 Huntington Disease - Pipeline by KineMed Inc, H2 2016 56 Huntington Disease - Pipeline by Krenitsky Pharmaceuticals Inc, H2 2016 57 Huntington Disease - Pipeline by Living Cell Technologies Ltd, H2 2016 58 Huntington Disease - Pipeline by Medesis Pharma SA, H2 2016 59 Huntington Disease - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 60 Huntington Disease - Pipeline by Neuralstem Inc, H2 2016 61 Huntington Disease - Pipeline by Neurimmune Holding AG, H2 2016 62 Huntington Disease - Pipeline by NeuroNascent Inc, H2 2016 63 Huntington Disease - Pipeline by New World Laboratories Inc, H2 2016 64 Huntington Disease - Pipeline by nLife Therapeutics SL, H2 2016 65 Huntington Disease - Pipeline by NsGene A/S, H2 2016 66 Huntington Disease - Pipeline by Omeros Corp, H2 2016 67 Huntington Disease - Pipeline by Oryzon Genomics SA, H2 2016 68 Huntington Disease - Pipeline by Pfizer Inc, H2 2016 69 Huntington Disease - Pipeline by PharmatrophiX Inc, H2 2016 70 Huntington Disease - Pipeline by ProQR Therapeutics NV, H2 2016 71 Huntington Disease - Pipeline by QR Pharma Inc, H2 2016 72 Huntington Disease - Pipeline by reMYND NV, H2 2016 73 Huntington Disease - Pipeline by Retrotope Inc, H2 2016 74 Huntington Disease - Pipeline by Rhenovia Pharma Ltd, H2 2016 75 Huntington Disease - Pipeline by Shire Plc, H2 2016 76 Huntington Disease - Pipeline by SOM Biotech SL, H2 2016 77 Huntington Disease - Pipeline by Spark Therapeutics Inc, H2 2016 78 Huntington Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 79 Huntington Disease - Pipeline by TyrNovo Ltd, H2 2016 80 Huntington Disease - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2016 81 Huntington Disease - Pipeline by UniQure NV, H2 2016 82 Huntington Disease - Pipeline by Vaccinex Inc, H2 2016 83 Huntington Disease - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 84 Huntington Disease - Pipeline by VistaGen Therapeutics Inc, H2 2016 85 Huntington Disease - Pipeline by Vitality Biopharma Inc, H2 2016 86 Huntington Disease - Pipeline by VivaCell Biotechnology Espana SL, H2 2016 87 Huntington Disease - Pipeline by Voyager Therapeutics Inc, H2 2016 88 Huntington Disease - Pipeline by Vybion Inc, H2 2016 89 Huntington Disease - Pipeline by WAVE Life Sciences Ltd, H2 2016 90 Huntington Disease - Pipeline by Wellstat Therapeutics Corp, H2 2016 91 Assessment by Monotherapy Products, H2 2016 92 Number of Products by Stage and Target, H2 2016 94 Number of Products by Stage and Mechanism of Action, H2 2016 97 Number of Products by Stage and Route of Administration, H2 2016 100 Number of Products by Stage and Molecule Type, H2 2016 102 Huntington Disease - Dormant Projects, H2 2016 272 Huntington Disease - Dormant Projects (Contd..1), H2 2016 273 Huntington Disease - Dormant Projects (Contd..2), H2 2016 274 Huntington Disease - Dormant Projects (Contd..3), H2 2016 275 Huntington Disease - Dormant Projects (Contd..4), H2 2016 276 Huntington Disease - Dormant Projects (Contd..5), H2 2016 277 Huntington Disease - Dormant Projects (Contd..6), H2 2016 278 Huntington Disease - Dormant Projects (Contd..7), H2 2016 279 Huntington Disease - Discontinued Products, H2 2016 280
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
